Tumour diploidy and survival in breast cancer patients with BRCA2 mutations.

Breast Cancer Res Treat 2013 Jul 16;140(2):375-84. Epub 2013 Jul 16.

Icelandic Cancer Registry, Icelandic Cancer Society, Skogarhlid 8, P.O. Box 5420, 125, Reykjavik, Iceland.

It is not well known to what extent carrying a BRCA2 mutation affects the survival of women with breast cancer and prognostic factors among BRCA2-positive women warrant investigation. Using a record linkage approach we compared the long-term survival in carriers and noncarriers of an inherited BRCA2 founder mutation (999del5), and sought to identify prognostic factors among the BRCA2 mutation-positive subset, including markers of genetic instability (aneuploidy) and mitotic activity (S-phase fraction). We established the genetic status of 2,967 Icelandic breast cancer patients (215 mutation carriers and 2,752 noncarriers) diagnosed from 1955 to 2004, representing 72 % of all cases diagnosed in the country during this period. Tumour ploidy and S-phase fraction were assessed on tumour cells by DNA flow cytometry. Prognostic factors were assessed blindly with respect to mutation status. Univariate and multivariate hazard ratios (HR) were estimated for breast cancer-specific survival by BRCA2 status, using Cox regression. After a median follow-up of 9.5 years, BRCA2 mutation carriers had a higher risk of death from breast cancer than noncarriers (HR 1.64, 95 % CI 1.24-2.16, p < 0.001). The risk increase was restricted to women with diploid tumours (HR 3.03, 95 % CI 1.91-4.79, p < 0.001). Among breast cancer patients with aneuploid tumours, survival of carriers was similar to that of noncarriers (HR 0.76, 95 % CI 0.41-1.41, p = 0.38). Increased tumour size and a positive nodal status predicted worse prognosis in all patients, whereas the highly correlated prognostic factors diploidy, low proliferative activity and a positive estrogen receptor status had reverse effects in mutation carriers and noncarriers. Breast cancer patients who carry the Icelandic founder BRCA2 mutation have inferior long-term survival than noncarriers, but the adverse prognosis is restricted to mutation carriers with diploid, slowly proliferating tumours.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-013-2637-4DOI Listing
July 2013
25 Reads
3.940 Impact Factor

Publication Analysis

Top Keywords

breast cancer
16
prognostic factors
12
cancer patients
8
brca2 mutation
8
mutation carriers
8
s-phase fraction
8
brca2
6
breast
5
mutation
5
brca2 status
4
patients 215
4
icelandic breast
4
2967 icelandic
4
genetic status
4
status 2967
4
mutation-positive subset
4
215 mutation
4
2752 noncarriers
4
noncarriers diagnosed
4
carriers 2752
4

References

(Supplied by CrossRef)

R Wooster et al.
Nature 1995

SV Tavtigian et al.
Nat Genet 1996

L Tryggvadottir et al.
J Natl Cancer Inst 2006

S Thorlacius et al.
Am J Hum Genet 1997

PJ Goodwin et al.
J Clin Oncol 2012

L Bordeleau et al.
Breast Cancer Res Treat 2010

EH Lee et al.
Breast Cancer Res Treat 2010

C Lengauer et al.
Nature 1998

BA Weaver et al.
Curr Opin Cell Biol 2006

H Rajagopalan et al.
Nature 2004

AR Venkitaraman et al.
Cell 2002

Similar Publications